Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2021 · 10-Q
Revenue$16.12M$16.12M+53.3% vs Q3 2020 Net Income$39.89K$39.89KN/M vs Q3 2020 EPS Diluted$0.00$0.00N/M vs Q3 2020 Gross Profit$9,077,119+50.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$204,928N/M Free Cash Flowderived$186,017N/M Margins · derivedGross margin56.3%−0.9 pt vs Q3 2020
Operating margin0.2%+1.9 pt vs Q3 2020
Net margin0.2%+2.9 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 9, 2021 · 40 d after period end